FY2024 EPS Estimates for Natera Lifted by Leerink Partnrs

Natera, Inc. (NASDAQ:NTRA) – Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Natera in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn ($1.27) per share for the year, up from their prior forecast of ($1.61). The consensus estimate for Natera’s current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Natera’s Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.19) EPS.

Several other research analysts have also recently commented on NTRA. JPMorgan Chase & Co. increased their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Guggenheim increased their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Morgan Stanley boosted their target price on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Robert W. Baird increased their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, Canaccord Genuity Group lifted their price objective on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $162.94.

Natera Trading Down 0.1 %

Natera stock opened at $171.82 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a 50-day moving average of $165.35 and a 200-day moving average of $135.41. The company has a market cap of $22.68 billion, a price-to-earnings ratio of -97.63 and a beta of 1.65. Natera has a one year low of $62.96 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the prior year, the company posted ($0.95) earnings per share. The firm’s revenue was up 63.9% on a year-over-year basis.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently added to or reduced their stakes in the stock. Chartwell Investment Partners LLC grew its holdings in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares in the last quarter. Cerity Partners LLC lifted its position in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Natera during the third quarter worth about $385,000. Everence Capital Management Inc. bought a new position in Natera in the 4th quarter valued at about $573,000. Finally, First Turn Management LLC acquired a new position in shares of Natera in the 3rd quarter valued at approximately $19,760,000. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 3,960 shares of Natera stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $468,111.60. Following the completion of the sale, the chief executive officer now owns 189,762 shares in the company, valued at $22,431,766.02. The trade was a 2.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roelof Botha sold 87,473 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the transaction, the director now owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. The trade was a 6.67 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 224,133 shares of company stock worth $36,830,652. Company insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.